Expression of AIF and HtrA2/Omi in small lymphocytic lymphoma and diffuse large B-cell lymphoma

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 7, 2011, Pages 903-908

  Li, Shaoying ^a,b   Wan, Mei ^a   Cao, Xu ^a   Ren, Yongsheng ^a  

^a UAB HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; MITOCHONDRIAL PROTEIN; SERINE PROTEINASE; SERINE PROTEINASE OMI;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE; MALE; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS INDUCING FACTOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; SERINE ENDOPEPTIDASES;

EID: 79960793828     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239-257.
2. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805): 770-776.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. (Pubitemid 30046295)
4. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106(2):408-418. (Pubitemid 40981231)
5. Fulda S. Cell death in hematological tumors. Apoptosis. 2009;14(4):409-423.
6. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol. 2003;4(3):211-218.
7. Kast RE, Altschuler EL. Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha. Arch Immunol Ther Exp. 2005; 53(2):143-147. (Pubitemid 41057864)
8. Pallasch CP, Wendtner CM. Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(3):498-501.
9. Ren Y, Akyurek N, Schlette E, Rassidakis GZ, Medeiros LJ. Expression of Smac/DIABLO in B-cell non-Hodgkin and Hodgkin lymphomas. Hum Pathol. 2006;37(11):1407-1413. (Pubitemid 44584334)
10. Danilov AV, Danilova OV, Klein AK, Huber BT. Molecular pathogenesis of chronic lymphocytic leukemia. Curr Mol Med. 2006;6(6):665-675. (Pubitemid 44377765)
11. Muris JJ, Meijer CJ, Ossenkoppele GJ, Vos W, Oudejans JJ. Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma. Hematol Oncol. 2006;24(3):97-104. (Pubitemid 44483901)
12. Muris JJ, Ylstra B, CillessenSA, etal. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. Br j Haematol. 2007;136(1):38-47. (Pubitemid 44912587)
13. Troutaud D, Petit B, Bellanger C, et al. Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(2):118-124.
14. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4(2):139-163. (Pubitemid 41351311)
15. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between lifeand death. Intl Biochem Cell Biol. 2007;39(7-8):1462-1475. (Pubitemid 47031030)
16. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17(6):1675-1687. (Pubitemid 28119121)
17. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004;23(16):2861-2874. (Pubitemid 38638848)
18. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998; 281(5381):1312-1316. (Pubitemid 28406817)
19. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 2004;64(20):7183-7190. (Pubitemid 39372048)
20. de Graaf AO, van Krieken JH, Tonnissen E, et al. Expression of C-IAP1, CIAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol. 2005,130(6):852-859. (Pubitemid 43899726)
21. Akyurek N, Ren Y, Rassidakis GZ, Schlette EJ, Medeiros LJ. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer. 2006;107(8):1844-1851. (Pubitemid 44582954)
22. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of 1AP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000;6(5): 1796-1803. (Pubitemid 30305074)
23. Wrzesien-Kus A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T. The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis. 2004;9(6):705-715. (Pubitemid 40941199)
24. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397(6718):441-446.
25. Porter AG, Urbano AG. Does apoptosis-inducing factor (AIF) have both life and death functions in cells ? Bioessays. 2006;28(8):834-843. (Pubitemid 44433745)
26. Klein JA, Longo-Guess CM, Rossmann MP, et al. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature. 2002;419(6905): 367-374.
27. Miramar MD, Costantini P, Ravagnan L, et al. NADH oxidase activity of mitochondrial apoptosis-inducing factor. J Biol Chem. 2001;276(19):16391-16398.
28. Ye H, Cande C, Stephanou NC, et al. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat Struct Biol. 2002;9(9):680-684. (Pubitemid 34977301)
29. Wang X, Yang C, Chai J, Shi Y, Xue D. Mechanisms of AlF-mediated apoptotic DNA degradation in Caenorhabditis elegans. Science. 2002;298(5598): 1587-1592. (Pubitemid 35387191)
30. Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K. BUB1 mediation of caspase-independent mitotic death determines cell fate. J Cell Biol. 2007;178(2): 283-296. (Pubitemid 47076464)
31. Vande Walle L, Lamkanfi M, Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ. 2008;15(3):453-460. (Pubitemid 351267296)
32. Li W, Srinivasula SM, Chai J, et al. Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. Nat Struct Biol. 2002;9(6): 436-441. (Pubitemid 34568788)
33. Guan JT, Wang L, Wang Y, et al. Expression of AIF and caspase-3 in colorectal carcinoma, adenoma, and normal mucosa and its correlation [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2009; 12(4):391-394.
34. Fan T, Jiang G, Suo Z, et al. Down-regulation of the apoptosis-inducing factor or Bcl-2 inhibitor of transcription by RNA interference can alleviate TAp63gamma-induced apoptosis in esophageal squamous carcinoma EC9706 cells. Int J Oncol. 2009;35(2):359-367.
35. Jeong EG, Lee JW, Soung YH, et al. Immunohistochemical and mutational analysis of apoptosis-inducing factor (AIF) in colorectal carcinomas. APMIS. 2006;114(12):867-873. (Pubitemid 44967322)
36. Lee JW, Jeong EG, Soung YH, et al. Immunohistochemical analysis of apoptosis-inducing factor (AIF) expression in gastric carcinomas. Pathol Res Pract. 2006;202(7):497-501. (Pubitemid 43871951)
37. Kempkensteffen C, Hinz S, Christoph F, et al. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J Cancer Res Clin Oncol. 2008; 134(5):543-550. (Pubitemid 351422608)
38. Lee SH, Lee JW, Kim HS, et al. Immunohistochemical analysis of OmiJ HtrA2 expression in stomach cancer. APMIS. 2003;111(5):586-590. (Pubitemid 36963179)
39. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25(34):4798-4811. (Pubitemid 44187627)
40. Lorenzo HK, Susin SA. Therapeutic potential of AlF-mediated caspaseindependent programmed cell death. Drug Resist Updat. 2007;10(6):235-255.
41. Wang M, Zhang L, Han X, et al. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007,109(12):5455-5462. (Pubitemid 46890569)